explore -WSS

explore

author：Wikipedia 2025-10-01 21:09:10 - browse：9457

Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.

The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.

RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： A new drug could help frostbite victims avoid its ravages

WSS

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Anesthesiologist group: stop taking Ozempic before surgery

Medicare Advantage enrollment hits roughly 33.4 million

23andMe had bad news about my health. I wish a person had delivered it

A new drug could help frostbite victims avoid its ravages

Ukraine seeks to reclaim its role as a hub for clinical trials

knowledge

explore

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

WATCH: Why do our ears pop?

Medicare proposal to cover medical devices draws a mixed reaction

Virginia high school admissions case could be legal follow

The high cost of giving birth even with insurance

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Supreme Court strikes down use of affirmative action

In age of alternative facts, a scholarly course on calling out crap

Jerome Adams on the need for new antivirals for Covid

Activists slam private health insurers over coverage restrictions

knowledge

Medicare Advantage enrollment grows 7.1% to 33.4 million people

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Reporting on presidential health from Reagan to Trump and Biden

New study raises questions about niacin and heart health

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

New CMS data security rules will hurt Medicare, Medicaid research

knowledge

hotspot

hotspot

leisure time